Completed Access to Information Requests

Follow:

  • RSS
  • Cite

    Cite

    APA

    Open Government - Government of Canada. (2017, December 10). Completed Access to Information Requests. Retrieved from http://open.canada.ca/en/search/ati?f%5B0%5D=ss_ati_organization_en%3AAtomic%20Energy%20of%20Canada%20Limited&amp%3Bamp%3Bf%5B1%5D=ss_ati_organization_en%3ACanadian%20Space%20Agency&amp%3Bamp%3Bf%5B2%5D=ss_ati_organization_en%3ADepartment%20of%20Finance%20Canada&amp%3Bati%5B0%5D=ss_ati_organization_en%3AOffice%20of%20the%20Privacy%20Commissioner%20of%20Canada&ati%5B0%5D=%3ANational%20Gallery%20of%20Canada&ati%5B1%5D=%3AOffice%20of%20the%20Superintendent%20of%20Financial%20Institutions%20Canada&ati%5B2%5D=%3APublic%20Service%20Commission%20of%20Canada&ati%5B3%5D=%3AShip-source%20Oil%20Pollution%20Fund&ati%5B4%5D=ati_month_en%3ASeptember&ati%5B5%5D=ati_organization_en%3AHealth%20Canada&search_api_fulltext=&sort_by=year&sort_order=DESC&f%5B0%5D=ss_ati_organization_en%3AAtomic%20Energy%20of%20Canada%20Limited&page=1
    MLA

    “Completed Access to Information Requests.” Open Government - Government of Canada, 10 December 2017, http://open.canada.ca/en/search/ati?f%5B0%5D=ss_ati_organization_en%3AAtomic%20Energy%20of%20Canada%20Limited&amp%3Bamp%3Bf%5B1%5D=ss_ati_organization_en%3ACanadian%20Space%20Agency&amp%3Bamp%3Bf%5B2%5D=ss_ati_organization_en%3ADepartment%20of%20Finance%20Canada&amp%3Bati%5B0%5D=ss_ati_organization_en%3AOffice%20of%20the%20Privacy%20Commissioner%20of%20Canada&ati%5B0%5D=%3ANational%20Gallery%20of%20Canada&ati%5B1%5D=%3AOffice%20of%20the%20Superintendent%20of%20Financial%20Institutions%20Canada&ati%5B2%5D=%3APublic%20Service%20Commission%20of%20Canada&ati%5B3%5D=%3AShip-source%20Oil%20Pollution%20Fund&ati%5B4%5D=ati_month_en%3ASeptember&ati%5B5%5D=ati_organization_en%3AHealth%20Canada&search_api_fulltext=&sort_by=year&sort_order=DESC&f%5B0%5D=ss_ati_organization_en%3AAtomic%20Energy%20of%20Canada%20Limited&page=1
    (Report an issue with citation)
About this information

Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA). For additional information, please see the “About Access to Information Requests” webpage.

If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.

*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.

Download datasets of the summaries of completed access to information requests.

Current Search

Report Type

Organization

Disposition

Year

Month

Found 369 record(s)

Req # A-2022-001093

The initial cover letter indicating the brand name of the reference drug product and the dosage form of the generic drug subject of the Abbreviated new Drug Submission (ANDS) which was added to Health Canada’s list of “Generic Drug Submissions Under Review” dated 2022-11-10 for the medicinal ingredient sapropterin hydrochloride. The Screening Acceptance Letter from Health Canada to the generic drug manufacturer confirming completion of screening of the Abbreviated New Drug Submissions (ANDS) for sapropterin hydrochloride.

Organization: Health Canada

2 page(s)
September 2023

Req # A-2022-001496

All records surrounding the development, planning, release and advertisement of the Medical Assistance in Dying (MAID) coloring book found here: https://www.virtualhospice.ca/maid/media/3bdlkrve/maid-activity-book.pdf. Limit search period from June 1st, 2019 to January 1st, 2021.

Organization: Health Canada

147 page(s)
September 2023

Req # A-2022-001497

All records surrounding the development, planning, release and advertisement of the Medical Assistance in Dying (MAID) coloring book found here: https://www.virtualhospice.ca/maid/media/3bdlkrve/maid-activity-book.pdf. Limit search period from January 1st, 2018 to June 1st, 2019.

Organization: Health Canada

63 page(s)
September 2023

Req # A-2022-001580

All available documentation relating to the registration of Natural Product Number (NPN) 80115682. Product names are Microsan Encore® Foaming Alcohol Handrub and Microsan® Optidose(TM) Foaming Alcohol Handrub by SC Johnson Professional CA Inc. Any available emails or meeting notes between the Sponsor and Health Canada throughout the registration process.

Organization: Health Canada

57 page(s)
September 2023

Req # A-2023-000008

The most recent draft copy of the State of Per and Polyfluoroalkyl Substances (PFAS) Report being prepared by Health Canada.

Organization: Health Canada

0 page(s)
September 2023

Req # A-2023-000155

The disclosable inspection document(s) listing the Inspector’s detailed observations, conditions found, and any follow-up expected by Health Canada for the human drugs drug establishment licence Good Manufacturing Practices (GMP) inspection of the Gilead Sciences facility (Site A) on Mississauga Rd.

Organization: Health Canada

47 page(s)
September 2023

Req # A-2023-000162

The safety summary reports of the hematological monitoring for GEN-Clozapine-associated neutropenia/agranulocytosis. Manufacturer: Mylan. The request references all marketed strengths of GEN-Clozapine tablets (Drug Indentification Numbers (DIN), 02247243, 02247244, 02305003 and 02305011).

Organization: Health Canada

859 page(s)
September 2023

Req # A-2023-000313

The licensed indications for use for MicroTheurapeutic‘s Axium Embolization Coils on Medical Device License 63475 that Health Canada has on file for this license.

Organization: Health Canada

160 page(s)
September 2023

Req # A-2023-000365

All notice of allegation (NOA) filing dates as outlined under sections 5(2.1)(c)(ii), (iii), and (iv) of the Patented Medicines (Notice of Compliance) Regulations, as well as the date in which the NOA was responded to by the first person for the following drugs, between the specified companies. AstraZeneca v Mylan VIMOVO; Merck Sharp & Dohme v Pharmascience JANUVIA; Teva v Pharmascience COPAXONE; Bristol-Myers Squibb v Mylan Pharmaceuticals SUSTIVA; Pfizer v Mylan Pharmaceuticals CELEBREX; Valeant v Generic Partners GLUMETZA; Janssen v Apotex OPSUMIT; Janssen vSandoz OPSUMIT; Alcon v Cobalt Pharmaceuticals PATANOL; Apotex v Shire VYVANSE; Eli Lilly v Mylan Pharmaceuticals CIALIS; Eli Lilly v Apotex CIALIS; Hoffman-La Roche v Apotex VALCYTE; Les Laboratoires Servier v Apotex VIACORAM; Eli Lilly v Teva ALIMTA; Janssen v Celltrion Healthcare REMICADE; Bayer v Apotex YAZ; Bayer v Cobalt Pharmaceuticals YAZ; Astrazeneca v Mylan Pharmaceuticals ARIMIDEX; Novartis Pharmaceuticals v Cobalt Pharmaceuticals Company ACLASTA; Teva v Janssen VELCADE; Laboratoires Servier v Apotex DIAMICRON MR; VIIV Healthcare v Teva KIVEXA; Gilead Sciences v Apotex TRUVADA; Sunovion Pharmaceuticals v Taro Pharmaceuticals LATUDA; Allergan v Sandoz COMBIGAN; Novartis Pharmaceuticals v Teva ZOMETA CONCENTRATE; Bayer v Sandoz ADEMPAS; Bayer v. Dr. Reddy‘s Laboratories Xarelto; Biomarin Pharmaceutical v. Dr. Reddy’s Laboratories KUVAN; Pfizer v Apotex CELEBREX; Bristol-Myers Squibb v Pharmascience ELIQUIS; Bristol-Myers Squibb & Gilead Sciences v Teva ATRIPLA; Purdue Pharma v Collegium Pharmaceuticals OXYNEO; Genentech v Amgen HERCEPTIN; Hoffmann-La Roche v Sandoz ESBRIET; Alcon v Apotex TRAVATAN Z; Janssen v Apotex INVEGA SUSTENNA; Janssen v Teva INVEGA SUSTENNA; Bristol-myers Squibb v Teva REYATAZ; Novo Nordisk v Teva VICTOZA; Bristol-Myers Squibb v Apotex SPRYCEL; Eli Lilly v NuPharm ZYPREXA; Valeant v Cobalt Pharmaceuticals TIAZAC XC; Eli Lilly v Apotex ADCIRCA; Shire v Cobalt Pharmaceuticals Company ADDERALL XR; AstraZeneca v Teva SEROQUEL XR; Eli Lilly v Hospira Healthcare Corporation ALIMTA; Alcon v Apotex Pataday; Valeant v Apotex GLUMETZA; Novartis Pharmaceuticals v Mylan Pharmaceuticals EXELON; Bristol-Myers Squibb v Sandoz ELIQUIS; Bristol-Myers Squibb v. Apotex ELIQUIS; AstraZeneca v Sandoz ONGLYZA; AstraZeneca v Sandoz KOMBOGLYZE; Takeda v Mylan TECTA; Janssen v Actavis Pharma CONCERTA; Pfizer v. Apotex PRISTIQ; Janssen v Apotex ZYTIGA; Janssen v Apotex ZYTIGA; Janssen v Dr Reddys Laboratories ZYTIGA; Bristol-Myers Squibb v Dr. Reddys Laboratories Zytiga; Janssen v Pharmascience ZYTIGA; Eli Lilly v Mylan CIALIS; Allergan v Apotex ZYMAR; Janssen v Apotex PREZISTA; Allergan v Apotex ACTONEL DR.

Organization: Health Canada

214 page(s)
September 2023

Req # A-2023-000384

Drafts and finalized version of the report on Sex and Gender-Based Analysis Plus (SGBA Plus) in Medical Devices presented to the Director General of Medical Devices Directorate (MDD) by the Scientific Advisory Committee on Health Products for Women.

Organization: Health Canada

395 page(s)
September 2023
Date modified: